Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2A Open-label Trial to Assess the Safety of ZIMURA (Anti-C5) Administered in Combination With LUCENTIS 0.5 mg in Treatment Naive Subjects With Neovascular Age Related Macular Degeneration

Trial Profile

A Phase 2A Open-label Trial to Assess the Safety of ZIMURA (Anti-C5) Administered in Combination With LUCENTIS 0.5 mg in Treatment Naive Subjects With Neovascular Age Related Macular Degeneration

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Nov 2018

At a glance

  • Drugs Avacincaptad pegol (Primary) ; Ranibizumab (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions; First in man
  • Sponsors OphthoTech Corporation
  • Most Recent Events

    • 14 Nov 2018 Status changed from active, no longer recruiting to completed.
    • 12 Nov 2018 Results presented in an OphthoTech Corporation media media release
    • 04 Oct 2018 According to an OphthoTech Corporation media release, top-line data from the trial is expected before the end of the year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top